1
|
Lai JD, Berlind JE, Fricklas G, Lie C, Urenda JP, Lam K, Sta Maria N, Jacobs R, Yu V, Zhao Z, Ichida JK. KCNJ2 inhibition mitigates mechanical injury in a human brain organoid model of traumatic brain injury. Cell Stem Cell 2024; 31:519-536.e8. [PMID: 38579683 DOI: 10.1016/j.stem.2024.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 11/21/2023] [Accepted: 03/06/2024] [Indexed: 04/07/2024]
Abstract
Traumatic brain injury (TBI) strongly correlates with neurodegenerative disease. However, it remains unclear which neurodegenerative mechanisms are intrinsic to the brain and which strategies most potently mitigate these processes. We developed a high-intensity ultrasound platform to inflict mechanical injury to induced pluripotent stem cell (iPSC)-derived cortical organoids. Mechanically injured organoids elicit classic hallmarks of TBI, including neuronal death, tau phosphorylation, and TDP-43 nuclear egress. We found that deep-layer neurons were particularly vulnerable to injury and that TDP-43 proteinopathy promotes cell death. Injured organoids derived from C9ORF72 amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) patients displayed exacerbated TDP-43 dysfunction. Using genome-wide CRISPR interference screening, we identified a mechanosensory channel, KCNJ2, whose inhibition potently mitigated neurodegenerative processes in vitro and in vivo, including in C9ORF72 ALS/FTD organoids. Thus, targeting KCNJ2 may reduce acute neuronal death after brain injury, and we present a scalable, genetically flexible cerebral organoid model that may enable the identification of additional modifiers of mechanical stress.
Collapse
Affiliation(s)
- Jesse D Lai
- Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Amgen Inc., Thousand Oaks, CA, USA; Neurological & Rare Diseases, Dewpoint Therapeutics, Boston, MA, USA.
| | - Joshua E Berlind
- Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA
| | - Gabriella Fricklas
- Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA
| | - Cecilia Lie
- Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA
| | - Jean-Paul Urenda
- Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA
| | - Kelsey Lam
- Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA
| | - Naomi Sta Maria
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Russell Jacobs
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Violeta Yu
- Amgen Inc., Thousand Oaks, CA, USA; Neurological & Rare Diseases, Dewpoint Therapeutics, Boston, MA, USA
| | - Zhen Zhao
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Justin K Ichida
- Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA; Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
| |
Collapse
|
2
|
El Karim IA, Duncan HF, Fouad AF, Taha NA, Yu V, Saber S, Ballal V, Chompu-Inwai P, Ahmed HMA, Gomes BPFA, Abushouk S, Cushley S, O'Neill C, Clarke M. Effectiveness of full Pulpotomy compared with Root canal treatment in managing teeth with signs and symptOms indicative of irreversible pulpitis: a protocol for prospectiVE meta-analysis of individual participant data of linked randomised clinical trials (PROVE). Trials 2023; 24:807. [PMID: 38102685 PMCID: PMC10722670 DOI: 10.1186/s13063-023-07836-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Accepted: 11/27/2023] [Indexed: 12/17/2023] Open
Abstract
BACKGROUND Full pulpotomy has been proposed as an alternative to root canal treatment in teeth with signs and symptoms indicative of irreversible pulpitis (IRP), but the evidence is limited, relying on underpowered studies with a high risk of bias. The aim of this study is to conduct a prospective meta-analysis (PMA) of individual participant data of a series of individual randomised trials to provide robust evidence on the clinical and cost-effectiveness of pulpotomy compared with root canal treatment. METHODS Individual participant data will be obtained from a series of randomised trials designed and conducted by a consortium of multi-national investigators with an interest in vital pulp treatment. These individualised trials will be conducted using a specified protocol, defined outcomes, and outcome measures. Ten parallel-group randomised trials currently being conducted in 10 countries will provide data from more than 500 participants. The primary outcome is a composite measure defined as (1) the absence of pain indicative of IRP, (2) the absence of signs and symptoms indicative of acute or chronic apical periodontitis, and (3) the absence of radiographic evidence of failure including radiolucency or resorption. Individual participant data will be obtained, assessed, and checked for quality by two independent reviewers prior to the PMA. Pooled estimates on treatment effects will be generated using a 2-stage meta-analysis approach. The first stage involves a standard regression analysis in each trial to produce aggregate data on treatment effect estimates followed by an inverse variance weighted meta-analysis to combine these aggregate data and produce summary statistics and forest plots. Cost-effectiveness analysis based on the composite outcome will be undertaken as a process evaluation to evaluate treatment fidelity and acceptability by patients and dentists. RESULTS The research question and trial protocol were developed and approved by investigators in all 10 sites. All sites use shared resources including study protocols, data collection forms, participant information leaflets, and consent forms in order to improve flow, consistency, and reproducibility. Each site obtained its own Institutional Review Board approval, and trials were registered in appropriate open access platforms. Patient recruitment has started in most sites, as of July 2023. DISCUSSION PMA offers a rigorous, flexible, and efficient methodology to answer this important research question and provide results with improved generalisability and external validity compared with traditional trials and retrospective meta-analyses. The results of this study will have implications for both the delivery of clinical practice and structured clinical guidelines' development. TRIAL REGISTRATION PROSPERO CRD42023446809. Registered on 08 February 2023.
Collapse
Affiliation(s)
- I A El Karim
- Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, The Wellcome-Wolfson Building, 97 Lisburn Road, Belfast, BT9 7AE, Northern Ireland, UK.
| | - H F Duncan
- Division of Restorative Dentistry & Periodontology, Dublin Dental University Hospital, Trinity College Dublin, Lincoln Place, Dublin 2, Ireland
| | - A F Fouad
- School of Dentistry, The University of Alabama at Birmingham, Birmingham, AL, USA
| | - N A Taha
- Department of Conservative Dentistry, Faculty of Dentistry, Jordan University of Science and Technology, Irbid, Jordan
| | - V Yu
- Faculty of Dentistry, National University of Singapore, Singapore, Singapore
| | - S Saber
- Department of Endodontics, Faculty of Dentistry, The British University, Cairo, Egypt
| | - V Ballal
- Department of Conservative Dentistry and Endodontics, Manipal College of Dental Sciences-ManipalManipal Academy of Higher Education, Manipal, India
| | - P Chompu-Inwai
- Division of Pediatric Dentistry, Department of Orthodontics and Pediatric Dentistry, School of Dentistry, Chiang Mai University, Chiang Mai, Thailand
| | - H M A Ahmed
- Department of Restorative Dentistry, Faculty of Dentistry, Universiti Malaya, Kuala Lumpur, Malaysia
| | - B P F A Gomes
- Department of Restorative Dentistry, Division of Endodontics, Piracicaba Dental School, State University of Campinas-UNICAMP, Av. Limeira Piracicaba, Areião, SP, 90113414-903, Brazil
| | - S Abushouk
- Department of Oral Rehabilitation, Faculty of Dentistry, Khartoum University, Khartoum, Sudan
| | - S Cushley
- Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, The Wellcome-Wolfson Building, 97 Lisburn Road, Belfast, BT9 7AE, Northern Ireland, UK
| | - C O'Neill
- Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, The Wellcome-Wolfson Building, 97 Lisburn Road, Belfast, BT9 7AE, Northern Ireland, UK
- Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Grosvenor Road, Belfast, BT12 6BJ, N. Ireland, UK
| | - M Clarke
- Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, The Wellcome-Wolfson Building, 97 Lisburn Road, Belfast, BT9 7AE, Northern Ireland, UK
- Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Grosvenor Road, Belfast, BT12 6BJ, N. Ireland, UK
| |
Collapse
|
3
|
Koshetova Z, Praliyev K, Yu V, Li T, Zhumanova N, Turaç E. Novel 3,5- bis(fluorobenzylidene)piperidin-4-ones as regulators of wheat growth. ijmph 2021. [DOI: 10.26577/ijbch.2021.v14.i2.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Daulet G, Baktybayeva L, Sokolenko A, Yu V, Malmakova A, Ten A, Berlin K, Zazybin G, Belyaev N. Biological activity of 4-ethynyl-, 4-oxy-, 4-butoxypropylpyperidine and azaheterocyclic compounds. ijbch 2021. [DOI: 10.26577/ijbch.2021.v14.i1.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
5
|
Sit J, Yuen X, Yu V. Early and intensive dietetic intervention on the nutritional status of nasopharyngeal cancer (NPC) patients undergoing radiotherapy (RT). Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Zhang H, Moyer BD, Yu V, McGivern JG, Jarosh M, Werley CA, Hecht VC, Babcock RJ, Dong K, Dempsey GT, McManus OB, Hempel CM. Correlation of Optical and Automated Patch Clamp Electrophysiology for Identification of Na V1.7 Inhibitors. SLAS Discov 2020; 25:434-446. [PMID: 32292096 DOI: 10.1177/2472555220914532] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The voltage-gated sodium channel Nav1.7 is a genetically validated target for pain; pharmacological blockers are promising as a new class of nonaddictive therapeutics. The search for Nav1.7 subtype selective inhibitors requires a reliable, scalable, and sensitive assay. Previously, we developed an all-optical electrophysiology (Optopatch) Spiking HEK platform to study activity-dependent modulation of Nav1.7 in a format compatible with high-throughput screening. In this study, we benchmarked the Optopatch Spiking HEK assay with an existing validated automated electrophysiology assay on the IonWorks Barracuda (IWB) platform. In a pilot screen of 3520 compounds, which included compound plates from a random library as well as compound plates enriched for Nav1.7 inhibitors, the Optopatch Spiking HEK assay identified 174 hits, of which 143 were confirmed by IWB. The Optopatch Spiking HEK assay maintained the high reliability afforded by traditional fluorescent assays and further demonstrated comparable sensitivity to IWB measurements. We speculate that the Optopatch assay could provide an affordable high-throughput screening platform to identify novel Nav1.7 subtype selective inhibitors with diverse mechanisms of action, if coupled with a multiwell parallel optogenetic recording instrument.
Collapse
Affiliation(s)
| | - Bryan D Moyer
- Neuroscience, Amgen Research, Thousand Oaks, CA, USA
| | - Violeta Yu
- Neuroscience, Amgen Research, Cambridge, MA, USA
| | - Joseph G McGivern
- Discovery Technologies, Amgen Research, South San Francisco, CA, USA
| | | | | | - Vivian C Hecht
- Q-State Biosciences, Cambridge, MA, USA.,Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Ryan J Babcock
- Q-State Biosciences, Cambridge, MA, USA.,Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Kevin Dong
- Q-State Biosciences, Cambridge, MA, USA.,Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | | | - Chris M Hempel
- Q-State Biosciences, Cambridge, MA, USA.,Expressive Neuroscience, Syracuse, NY, USA
| |
Collapse
|
7
|
Chao M, Spencer S, Kai C, Baker C, Jassal S, Law M, Cheng M, Zantuck N, Yu V, Stoney D, Loh S, Bevington E, Chew G, Hyett A, Guerrieri M, Ho H, Ng M, Wasiak J, Foroudi F. EP-1286 StrataXRT is non inferior to Mepitel Film in preventing radiation induced moist desquamation. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31706-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Moyer BD, Murray JK, Ligutti J, Andrews K, Favreau P, Jordan JB, Lee JH, Liu D, Long J, Sham K, Shi L, Stöcklin R, Wu B, Yin R, Yu V, Zou A, Biswas K, Miranda LP. Pharmacological characterization of potent and selective NaV1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V. PLoS One 2018; 13:e0196791. [PMID: 29723257 PMCID: PMC5933747 DOI: 10.1371/journal.pone.0196791] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Accepted: 04/19/2018] [Indexed: 11/18/2022] Open
Abstract
Identification of voltage-gated sodium channel NaV1.7 inhibitors for chronic pain therapeutic development is an area of vigorous pursuit. In an effort to identify more potent leads compared to our previously reported GpTx-1 peptide series, electrophysiology screening of fractionated tarantula venom discovered the NaV1.7 inhibitory peptide JzTx-V from the Chinese earth tiger tarantula Chilobrachys jingzhao. The parent peptide displayed nominal selectivity over the skeletal muscle NaV1.4 channel. Attribute-based positional scan analoging identified a key Ile28Glu mutation that improved NaV1.4 selectivity over 100-fold, and further optimization yielded the potent and selective peptide leads AM-8145 and AM-0422. NMR analyses revealed that the Ile28Glu substitution changed peptide conformation, pointing to a structural rationale for the selectivity gains. AM-8145 and AM-0422 as well as GpTx-1 and HwTx-IV competed for ProTx-II binding in HEK293 cells expressing human NaV1.7, suggesting that these NaV1.7 inhibitory peptides interact with a similar binding site. AM-8145 potently blocked native tetrodotoxin-sensitive (TTX-S) channels in mouse dorsal root ganglia (DRG) neurons, exhibited 30- to 120-fold selectivity over other human TTX-S channels and exhibited over 1,000-fold selectivity over other human tetrodotoxin-resistant (TTX-R) channels. Leveraging NaV1.7-NaV1.5 chimeras containing various voltage-sensor and pore regions, AM-8145 mapped to the second voltage-sensor domain of NaV1.7. AM-0422, but not the inactive peptide analog AM-8374, dose-dependently blocked capsaicin-induced DRG neuron action potential firing using a multi-electrode array readout and mechanically-induced C-fiber spiking in a saphenous skin-nerve preparation. Collectively, AM-8145 and AM-0422 represent potent, new engineered NaV1.7 inhibitory peptides derived from the JzTx-V scaffold with improved NaV selectivity and biological activity in blocking action potential firing in both DRG neurons and C-fibers.
Collapse
Affiliation(s)
- Bryan D. Moyer
- Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America
- * E-mail:
| | - Justin K. Murray
- Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Joseph Ligutti
- Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Kristin Andrews
- Molecular Engineering, Amgen Discovery Research, Cambridge, Massachusetts, United States of America
| | | | - John B. Jordan
- Discovery Attribute Sciences, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Josie H. Lee
- Neuroscience, Amgen Discovery Research, Cambridge, Massachusetts, United States of America
| | - Dong Liu
- Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Jason Long
- Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Kelvin Sham
- Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Licheng Shi
- Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Reto Stöcklin
- Atheris Laboratories, CH Bernex, Geneva, Switzerland
| | - Bin Wu
- Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Ruoyuan Yin
- Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Violeta Yu
- Neuroscience, Amgen Discovery Research, Cambridge, Massachusetts, United States of America
| | - Anruo Zou
- Neuroscience, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Kaustav Biswas
- Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America
| | - Les P. Miranda
- Therapeutic Discovery, Amgen Discovery Research, Thousand Oaks, California, United States of America
| |
Collapse
|
9
|
Kim D, Chen R, Kim S, Park A, Evans B, Yu V, Oh E, Miller L, Kang S, Ghiaur G, Yu J, Huang W, Kane M, Garza L. 1410 Non-coding double stranded RNA induces retinoic acid synthesis and retinoid signaling to control regeneration. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.1428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
10
|
Chao M, Foroudi F, Jassal S, Hyett A, Neoh D, Bevington E, Loh S, Zantuck N, Stoney D, Guerrieri M, Foley C, Grinsell D, Law M, Cheng M, Yu V, Chew G, Taylor K, David C, Chipman M, Baker C. Tumor down staging in high risk or locally advanced breast cancer patients undergoing neoadjuvant radiotherapy prior to definitive surgery and autologous breast reconstruction. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30397-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Chao M, Foroudi F, Jassal S, Hyett A, Neoh D, Bevington E, Stoney D, Zantuck N, Law M, Foley C, Guerrieri M, Grinsell D, Loh S, Chew G, Yu V, Cokelek M, Taylor K, Cheng M, Chipman M, Baker C. The use of neoadjuvant radiotherapy in high risk or locally advanced breast cancer patients prior to definitive surgery with mastectomy and autologous breast reconstruction does not impact on post operative surgical complications. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30419-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Baker C, Chao MW, Jassal S, Neoh D, Bevington E, Hyett A, Grinsell D, Loh SW, Zantuck N, Stoney D, Foley C, Law M, Chew G, Yu V, Cheng M, Guerrieri M, Taylor K, Chipman M, Cokelek M, Lim Joon D, Foroudi F. Abstract P2-11-16: The safety and pathological impact of neoadjuvant radiotherapy for local advanced breast cancer undergoing mastectomy and autologous reconstruction. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-11-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Delayed breast reconstructions are preferred if post mastectomy radiotherapy is indicated due to lower complication rates compared to immediate permanent implant or autologous reconstructions (AR) but cosmetic outcomes are inferior. Radiotherapy has a deleterious effect on implants and autologous tissue and often an interim tissue expander is place which has inherent pain and complications.
However, neoadjuvant radiotherapy (NART) prior to surgery allows for definitive oncological surgery to be performed with an immediate AR in a single operation and the avoidance of a temporary expander. The aim of this study is to assess the safety and downstaging impact of NART.
Methods
This is a prospective review of patients who underwent NART at GenesisCare Victoria, the Austin and the Alfred hospital. 59 LABC patients (median age 49.2 years) were divided into two groups; clinically staged and pathologically staged for reporting. There were 15 pathologically staged patients (pStage 2A-3C) and 43 clinically staged patients (cStage 2A-3B). All patients initially underwent NACT, followed by NART (median dose 50.4Gy in 28 fractions) to the breast, supraclavicular fossa and level 3 axilla with or without coverage of their Level 1 and 2 axilla, and/or internal mammary nodes. Approximately 6 weeks after completing NART, patients underwent definitive surgery and AR.
Results
All patients completed their NART with minimal toxicity and no break in treatment. 55 patients had a skin-sparing mastectomy (SSM) and 3 patients had a modified radical mastectomy. All clinically staged patients underwent an AD. ARs with a DIEP flap were performed in the majority of patients (51). The average length of hospitalisation was 6.2 days.
The Miller Payne (MP) scoring index was used to record pathological responses in clinically staged patients. Overall 36 patients achieved significant downstaging of their disease, with MP scores of 5/5 for 20 and 4/5 for 16. Only 1 patient failed to achieve any downstaging with a MP score of 1/5. All 12 Her2 positive patients, 3/5 Triple negative patients and 5/26 Luminal A/B patients achieved a MP score of 5/5. All patients achieved R0 resection margins. This included 6 patients who had initial cT4 disease (cT4a X2, cT4b X1 and cT4d X3). 15 patients had initial cN2/3 disease and all successfully underwent their axillary dissections with R0 resections achieved. 10/15 had no involved axillary nodes with significant scarring seen in 6. 5/15 had residual involved nodes with significant scarring seen in 3 patients.
Post surgical toxicities were graded using Clavien-Dindo classification. 8 significant grade 3 toxicities were seen in 6 patients, with no grade 4 or 5 toxicities. No patients developed DVT or PE. No flap losses were seen.
Median follow up is 23 months. Cosmesis was rated as good to excellent in all cases. 1 patient developed simultaneous loco-regional and distant recurrence with another 3 patients developing distant metastases only.
Conclusion
This review demonstrated that NART is a safe technique, which has not lead to an increase in surgical complication rates or resulted in a detriment in cosmetic outcome. NART can achieve a shorter, simpler reconstructive journey for patients.
Citation Format: Baker C, Chao MW, Jassal S, Neoh D, Bevington E, Hyett A, Grinsell D, Loh SW, Zantuck N, Stoney D, Foley C, Law M, Chew G, Yu V, Cheng M, Guerrieri M, Taylor K, Chipman M, Cokelek M, Lim Joon D, Foroudi F. The safety and pathological impact of neoadjuvant radiotherapy for local advanced breast cancer undergoing mastectomy and autologous reconstruction [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-11-16.
Collapse
Affiliation(s)
- C Baker
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - MW Chao
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - S Jassal
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - D Neoh
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - E Bevington
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - A Hyett
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - D Grinsell
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - SW Loh
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - N Zantuck
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - D Stoney
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - C Foley
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - M Law
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - G Chew
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - V Yu
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - M Cheng
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - M Guerrieri
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - K Taylor
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - M Chipman
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - M Cokelek
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - D Lim Joon
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| | - F Foroudi
- St Vincents Hospital, Melbourne, Victoria, Australia; Victorian Breast and Oncology Centre, Melbourne, Victoria, Australia; Genesis Care Cancer Centre, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Maroondah Hospital, Melbourne, Victoria, Australia; Alfred Hospital, Melbourne, Victoria, Australia
| |
Collapse
|
13
|
Zazybin AG, Rafikova K, Yu V, Zolotareva D, Dembitsky VM, Sasaki T. Metal-containing ionic liquids: current paradigm and applications. Russ Chem Rev 2017. [DOI: 10.1070/rcr4743] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
14
|
Cokelek M, Chao M, Foroudi F, Jassal S, Neoh D, Bevington E, Hyett A, Grinsell D, Loh S, Zantuck N, Stoney D, Foley C, Law M, Yu V, Chew G, Cheng M, Taylor K, Guerrieri M, Chipman M, Baker C. Sequence Reversal: Neoadjuvant Radiation Therapy for Locally Advanced Breast Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
La DS, Peterson EA, Bode C, Boezio AA, Bregman H, Chu-Moyer MY, Coats J, DiMauro EF, Dineen TA, Du B, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Fremeau R, Huang X, Ilch C, Kornecook TJ, Kreiman C, Ligutti J, Jasmine Lin MH, McDermott JS, Marx I, Matson DJ, McDonough SI, Moyer BD, Nho Nguyen H, Taborn K, Yu V, Weiss MM. The discovery of benzoxazine sulfonamide inhibitors of Na V 1.7: Tools that bridge efficacy and target engagement. Bioorg Med Chem Lett 2017. [DOI: 10.1016/j.bmcl.2017.05.070] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
16
|
Ghezelayagh T, Stewart L, Yu V, Agnew K, Norquist B, Pennington K, Swisher E. Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Kornecook TJ, Yin R, Altmann S, Be X, Berry V, Ilch CP, Jarosh M, Johnson D, Lee JH, Lehto SG, Ligutti J, Liu D, Luther J, Matson D, Ortuno D, Roberts J, Taborn K, Wang J, Weiss MM, Yu V, Zhu DXD, Fremeau RT, Moyer BD. Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7. J Pharmacol Exp Ther 2017; 362:146-160. [DOI: 10.1124/jpet.116.239590] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 05/03/2017] [Indexed: 02/05/2023] Open
|
18
|
Weiss MM, Dineen TA, Marx IE, Altmann S, Boezio A, Bregman H, Chu-Moyer M, DiMauro EF, Feric Bojic E, Foti RS, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Huang H, Huang L, Jarosh M, Kornecook T, Kreiman CR, Ligutti J, La DS, Lin MHJ, Liu D, Moyer BD, Nguyen HN, Peterson EA, Rose PE, Taborn K, Youngblood BD, Yu V, Fremeau RT. Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. J Med Chem 2017; 60:5969-5989. [DOI: 10.1021/acs.jmedchem.6b01851] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Thomas Kornecook
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | - Joseph Ligutti
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | - Dong Liu
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Bryan D. Moyer
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio C, Butler JR, Chu-Moyer M, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT, Guzman-Perez A, Gao H, Gunaydin H, Huang H, Huang L, Ilch C, Jarosh M, Kornecook T, Kreiman CR, La DS, Ligutti J, Milgram BC, Lin MHJ, Marx IE, Nguyen HN, Peterson EA, Rescourio G, Roberts J, Schenkel L, Shimanovich R, Sparling BA, Stellwagen J, Taborn K, Vaida KR, Wang J, Yeoman J, Yu V, Zhu D, Moyer BD, Weiss MM. Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity. J Med Chem 2017; 60:5990-6017. [DOI: 10.1021/acs.jmedchem.6b01850] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
| | | | - Jessica Able
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Thomas Kornecook
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | - Joseph Ligutti
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Bryan D. Moyer
- Department
of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | |
Collapse
|
20
|
Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MHJ, Liu D, McDermott JS, Moyer BD, Nguyen HN, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM. Correction to "Sulfonamides as Selective Na V1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement". ACS Med Chem Lett 2017; 8:378. [PMID: 28337335 DOI: 10.1021/acsmedchemlett.7b00075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
[This corrects the article DOI: 10.1021/acsmedchemlett.6b00243.].
Collapse
|
21
|
Marx IE, Dineen TA, Able J, Bode C, Bregman H, Chu-Moyer M, DiMauro EF, Du B, Foti RS, Fremeau RT, Gao H, Gunaydin H, Hall BE, Huang L, Kornecook T, Kreiman CR, La DS, Ligutti J, Lin MHJ, Liu D, McDermott JS, Moyer BD, Peterson EA, Roberts JT, Rose P, Wang J, Youngblood BD, Yu V, Weiss MM. Sulfonamides as Selective Na V1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement. ACS Med Chem Lett 2016; 7:1062-1067. [PMID: 27994738 DOI: 10.1021/acsmedchemlett.6b00243] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Accepted: 09/21/2016] [Indexed: 11/29/2022] Open
Abstract
Human genetic evidence has identified the voltage-gated sodium channel NaV1.7 as an attractive target for the treatment of pain. We initially identified naphthalene sulfonamide 3 as a potent and selective inhibitor of NaV1.7. Optimization to reduce biliary clearance by balancing hydrophilicity and hydrophobicity (Log D) while maintaining NaV1.7 potency led to the identification of quinazoline 16 (AM-2099). Compound 16 demonstrated a favorable pharmacokinetic profile in rat and dog and demonstrated dose-dependent reduction of histamine-induced scratching bouts in a mouse behavioral model following oral dosing.
Collapse
Affiliation(s)
- Isaac E. Marx
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Thomas A. Dineen
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Jessica Able
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Christiane Bode
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Howard Bregman
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Margaret Chu-Moyer
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Erin F. DiMauro
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Bingfan Du
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Robert S. Foti
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Robert T. Fremeau
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Hua Gao
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Hakan Gunaydin
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Brian E. Hall
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Liyue Huang
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Thomas Kornecook
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Charles R. Kreiman
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Daniel S. La
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Joseph Ligutti
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Min-Hwa Jasmine Lin
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Dong Liu
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Jeff S. McDermott
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Bryan D. Moyer
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Emily A. Peterson
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Jonathan T. Roberts
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Paul Rose
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Jean Wang
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Beth D. Youngblood
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Violeta Yu
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| | - Matthew M. Weiss
- Department of Medicinal
Chemistry, ‡Department of Molecular Engineering, §Department of Pharmacokinetics
and Drug Metabolism, ∥Department of Neuroscience, and ⊥Department of Biologics, Amgen, Inc., 360 Binney
Street, Cambridge, Massachusetts 02142, and One Amgen Center Drive, Thousand
Oaks, California 91320, United States
| |
Collapse
|
22
|
DiMauro EF, Altmann S, Berry LM, Bregman H, Chakka N, Chu-Moyer M, Bojic EF, Foti RS, Fremeau R, Gao H, Gunaydin H, Guzman-Perez A, Hall BE, Huang H, Jarosh M, Kornecook T, Lee J, Ligutti J, Liu D, Moyer BD, Ortuno D, Rose PE, Schenkel LB, Taborn K, Wang J, Wang Y, Yu V, Weiss MM. Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. J Med Chem 2016; 59:7818-39. [DOI: 10.1021/acs.jmedchem.6b00425] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | - Robert Fremeau
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | - Thomas Kornecook
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | - Joseph Ligutti
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Dong Liu
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Bryan D. Moyer
- Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Yu V, Ruan D, Nguyen D, Kaprealian T, Chin R, Sheng K. SU-F-R-17: Advancing Glioblastoma Multiforme (GBM) Recurrence Detection with MRI Image Texture Feature Extraction and Machine Learning. Med Phys 2016. [DOI: 10.1118/1.4955789] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
24
|
Yu V. TH-AB-BRB-04: Quality Assurance for Advanced Digital Linac Implementations. Med Phys 2016. [DOI: 10.1118/1.4958050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
25
|
Woods K, Karunamuni R, Tran A, Yu V, Nguyen D, Hattangadi-Gluth J, Sheng K. TH-EF-BRB-01: BEST IN PHYSICS (THERAPY): Dosimetric Comparison of 4π and Clinical IMRT for Cortex-Sparing High-Grade Glioma Treatment. Med Phys 2016. [DOI: 10.1118/1.4958247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
26
|
Tran A, Ruan D, Woods K, Yu V, Nguyen D, Sheng K. SU-D-BRB-01: A Comparison of Learning Methods for Knowledge Based Dose Prediction for Coplanar and Non-Coplanar Liver Radiotherapy. Med Phys 2016. [DOI: 10.1118/1.4955627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
27
|
Yu V, Tran A, Nguyen D, Woods K, Cao M, Kaprealian T, Chin R, Low D, Sheng K. TH-EF-BRB-03: Significant Cord and Esophagus Dose Reduction by 4π Non-Coplanar Spine Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery. Med Phys 2016. [DOI: 10.1118/1.4958249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
28
|
Neylon J, Sheng K, Yu V, Chen Q, Low DA, Kupelian P, Santhanam A. A nonvoxel-based dose convolution/superposition algorithm optimized for scalable GPU architectures. Med Phys 2015; 41:101711. [PMID: 25281950 DOI: 10.1118/1.4895822] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Real-time adaptive planning and treatment has been infeasible due in part to its high computational complexity. There have been many recent efforts to utilize graphics processing units (GPUs) to accelerate the computational performance and dose accuracy in radiation therapy. Data structure and memory access patterns are the key GPU factors that determine the computational performance and accuracy. In this paper, the authors present a nonvoxel-based (NVB) approach to maximize computational and memory access efficiency and throughput on the GPU. METHODS The proposed algorithm employs a ray-tracing mechanism to restructure the 3D data sets computed from the CT anatomy into a nonvoxel-based framework. In a process that takes only a few milliseconds of computing time, the algorithm restructured the data sets by ray-tracing through precalculated CT volumes to realign the coordinate system along the convolution direction, as defined by zenithal and azimuthal angles. During the ray-tracing step, the data were resampled according to radial sampling and parallel ray-spacing parameters making the algorithm independent of the original CT resolution. The nonvoxel-based algorithm presented in this paper also demonstrated a trade-off in computational performance and dose accuracy for different coordinate system configurations. In order to find the best balance between the computed speedup and the accuracy, the authors employed an exhaustive parameter search on all sampling parameters that defined the coordinate system configuration: zenithal, azimuthal, and radial sampling of the convolution algorithm, as well as the parallel ray spacing during ray tracing. The angular sampling parameters were varied between 4 and 48 discrete angles, while both radial sampling and parallel ray spacing were varied from 0.5 to 10 mm. The gamma distribution analysis method (γ) was used to compare the dose distributions using 2% and 2 mm dose difference and distance-to-agreement criteria, respectively. Accuracy was investigated using three distinct phantoms with varied geometries and heterogeneities and on a series of 14 segmented lung CT data sets. Performance gains were calculated using three 256 mm cube homogenous water phantoms, with isotropic voxel dimensions of 1, 2, and 4 mm. RESULTS The nonvoxel-based GPU algorithm was independent of the data size and provided significant computational gains over the CPU algorithm for large CT data sizes. The parameter search analysis also showed that the ray combination of 8 zenithal and 8 azimuthal angles along with 1 mm radial sampling and 2 mm parallel ray spacing maintained dose accuracy with greater than 99% of voxels passing the γ test. Combining the acceleration obtained from GPU parallelization with the sampling optimization, the authors achieved a total performance improvement factor of >175 000 when compared to our voxel-based ground truth CPU benchmark and a factor of 20 compared with a voxel-based GPU dose convolution method. CONCLUSIONS The nonvoxel-based convolution method yielded substantial performance improvements over a generic GPU implementation, while maintaining accuracy as compared to a CPU computed ground truth dose distribution. Such an algorithm can be a key contribution toward developing tools for adaptive radiation therapy systems.
Collapse
Affiliation(s)
- J Neylon
- Department of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, #B265, Los Angeles, California 90095
| | - K Sheng
- Department of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, #B265, Los Angeles, California 90095
| | - V Yu
- Department of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, #B265, Los Angeles, California 90095
| | - Q Chen
- Department of Radiation Oncology, University of Virginia, 1300 Jefferson Park Avenue, Charlottesville, California 22908
| | - D A Low
- Department of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, #B265, Los Angeles, California 90095
| | - P Kupelian
- Department of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, #B265, Los Angeles, California 90095
| | - A Santhanam
- Department of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, #B265, Los Angeles, California 90095
| |
Collapse
|
29
|
Nguyen D, O'Connor D, Yu V, Ruan D, Cao M, Low D, Sheng K. TH-EF-BRD-05: A New Intensity Modulation Radiation Therapy (IMRT) Optimizer Solution with Robust Fluence Maps for MLC Segmentation. Med Phys 2015. [DOI: 10.1118/1.4926292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
30
|
Tran A, Yu V, Nguyen D, Woods K, Low D, Sheng K. SU-F-BRB-10: A Statistical Voxel Based Normal Organ Dose Prediction Model for Coplanar and Non-Coplanar Prostate Radiotherapy. Med Phys 2015. [DOI: 10.1118/1.4925205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
31
|
Yu V, Nguyen D, Tran A, Ruan D, Cao M, Kaprealian T, Kupelian P, Low D, Sheng K. TU-CD-304-05: 4Ï€ Non-Coplanar Radiotherapy: From Mathematical Modeling to Clinical Implementation. Med Phys 2015. [DOI: 10.1118/1.4925574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
32
|
Tran A, Zhang J, Woods K, Yu V, Nguyen D, Sheng K. SU-E-T-765: Treatment Planning Comparison of SFUD Proton and 4Ï€ Radiotherapy for Prostate Cases. Med Phys 2015. [DOI: 10.1118/1.4925129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Yu V, Nguyen D, Pajonk F, Kaprealian T, Kupelian P, Steinberg M, Low D, Sheng K. SU-D-BRB-06: Treating Glioblastoma Multiforme (GBM) as a Chronic Disease: Implication of Temporal-Spatial Dose Fractionation Optimization Including Cancer Stem Cell Dynamics. Med Phys 2015. [DOI: 10.1118/1.4923879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
34
|
Woods K, Nguyen D, Tran A, Yu V, Cao M, Sheng K. SU-F-BRB-04: Comparison of Coplanar VMAT, Non-Coplanar VMAT, and 4π Treatment Plans. Med Phys 2015. [DOI: 10.1118/1.4925199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
35
|
Yu V, Nguyen D, Kupelian P, Kaprealian T, Selch M, Low D, Pajonk F, Sheng K. SU-C-BRE-03: Dual Compartment Mathematical Modeling of Glioblastoma Multiforme (GBM). Med Phys 2014. [DOI: 10.1118/1.4889709] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
36
|
Nguyen D, Rwigema J, Yu V, Kaprealian T, Kupelian P, Selch M, Low D, Sheng K. SU-E-T-183: Feasibility of Extreme Dose Escalation for Glioblastoma Multiforme Using 4π Radiotherapy. Med Phys 2014. [DOI: 10.1118/1.4888513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
37
|
Nguyen D, Yu V, Ruan D, Semwal H, O’Connor D, Cao M, Low D, Sheng K. TU-C-17A-05: Dose Domain Optimization of MLC Leaf Patterns for Highly Complicated 4Ï€ IMRT Plans. Med Phys 2014. [DOI: 10.1118/1.4889280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
38
|
Kishan A, Wang J, Yu V, Ruan D, Cao M, Tenn S, Low D, Lee P. Correlation of Clinical and Dosimetric Parameters With Radiographic Lung Injury Following Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1333] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Kwan BCH, Chow KM, Leung CB, Law MC, Cheng PMS, Yu V, Li PKT, Szeto CC. Circulating bacterial-derived DNA fragments as a marker * of systemic inflammation in peritoneal dialysis. Nephrol Dial Transplant 2013; 28:2139-2145. [DOI: 10.1093/ndt/gft100] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
40
|
Yu V, Kishan A, Lee P, Low D, Ruan D. SU-C-141-01: Dose Impact in Lung Fibrosis Following Lung SBRT: Statistical Analysis and Geometric Interpretation. Med Phys 2013. [DOI: 10.1118/1.4813961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
41
|
Simard JR, Plant M, Emkey R, Yu V. Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase. Assay Drug Dev Technol 2013; 11:152-62. [PMID: 23409774 DOI: 10.1089/adt.2012.481] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The methylation state of lysine residues within histone H3 is a major determinant of active and inactive regions of the genome. Enhancer of Zeste homolog 2 (EZH2) is a histone lysine methyltransferase that is part of the polycomb repressive complex 2 (PRC2). Elevated EZH2 expression levels have been linked to hypertrimethylation of histone H3 lysine 27 (H3K27), repression of tumor repressor genes, and the onset of several types of cancers. We used the AlphaLISA technology to develop a high-throughput assay for identifying small molecule inhibitors of EZH2. AlphaLISA Acceptor Beads coated with antibodies directed against methylated H3K27 provided a sensitive method of detecting EZH2 activity through measurement of K27 methylation of a biotinylated H3-based peptide substrate. Optimized assay conditions resulted in a robust assay (Z'>0.7) which was successfully implemented in a high-throughput screening campaign. Small molecule inhibitors identified by this method may serve as powerful tools to further elucidate the potential importance of EZH2 in the development and treatment of cancer.
Collapse
|
42
|
Huang H, Acquaviva L, Berry V, Bregman H, Chakka N, O’Connor A, DiMauro EF, Dovey J, Epstein O, Grubinska B, Goldstein J, Gunaydin H, Hua Z, Huang X, Huang L, Human J, Long A, Newcomb J, Patel VF, Saffran D, Serafino R, Schneider S, Strathdee C, Tang J, Turci S, White R, Yu V, Zhao H, Wilson C, Martin MW. Structure-Based Design of Potent and Selective CK1γ Inhibitors. ACS Med Chem Lett 2012; 3:1059-64. [PMID: 24900428 DOI: 10.1021/ml300278f] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2012] [Accepted: 10/18/2012] [Indexed: 12/20/2022] Open
Abstract
Aberrant activation of the Wnt pathway is believed to drive the development and growth of some cancers. The central role of CK1γ in Wnt signal transduction makes it an attractive target for the treatment of Wnt-pathway dependent cancers. We describe a structure-based approach that led to the discovery of a series of pyridyl pyrrolopyridinones as potent and selective CK1γ inhibitors. These compounds exhibited good enzyme and cell potency, as well as selectivity against other CK1 isoforms. A single oral dose of compound 13 resulted in significant inhibition of LRP6 phosphorylation in a mouse tumor PD model.
Collapse
Affiliation(s)
- Hongbing Huang
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Lisa Acquaviva
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Virginia Berry
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Howard Bregman
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Nagasree Chakka
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Anne O’Connor
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Erin F. DiMauro
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Jennifer Dovey
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Oleg Epstein
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Barbara Grubinska
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Jon Goldstein
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Hakan Gunaydin
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Zihao Hua
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Xin Huang
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Liyue Huang
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Jason Human
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Alex Long
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - John Newcomb
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Vinod F. Patel
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Doug Saffran
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Randy Serafino
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Steve Schneider
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Craig Strathdee
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Jin Tang
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Susan Turci
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Ryan White
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Violeta Yu
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Huilin Zhao
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Cindy Wilson
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| | - Matthew W. Martin
- Departments of †Medicinal Chemistry; ‡Pharmacokinetics and Drug Metabolism; §Oncology Research; and ∥Molecular Structure, Amgen Inc., 360 Binney Street, Cambridge,
Massachusetts 02142, United States
| |
Collapse
|
43
|
Fahimian B, Yu V, Xing L, Horst K, Hristov D. Prone Partial Breast Coronal Arc Irradiation: Combining Intensity Modulated Delivery With Dynamic Motion of the Couch. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.555] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
44
|
Schenkel LB, Huang X, Cheng A, Deak HL, Doherty E, Emkey R, Gu Y, Gunaydin H, Kim JL, Lee J, Loberg R, Olivieri P, Pistillo J, Tang J, Wan Q, Wang HL, Wang SW, Wells MC, Wu B, Yu V, Liu L, Geuns-Meyer S. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. J Med Chem 2011; 54:8440-50. [PMID: 22087750 DOI: 10.1021/jm200911r] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Developing Janus kinase 2 (Jak2) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a Jak2 gain-of-function mutation in the majority of patients with myeloproliferative disorders (MPD). Here, we describe the discovery of a thienopyridine series of Jak2 inhibitors that culminates with compounds showing 100- to >500-fold selectivity over the related Jak family kinases in enzyme assays. Selectivity for Jak2 was also observed in TEL-Jak cellular assays, as well as in cytokine-stimulated peripheral blood mononuclear cell (PBMC) and whole blood assays. X-ray cocrystal structures of 8 and 19 bound to the Jak2 kinase domain aided structure-activity relationship efforts and, along with a previously reported small molecule X-ray cocrystal structure of the Jak1 kinase domain, provided structural rationale for the observed high levels of Jak2 selectivity.
Collapse
Affiliation(s)
- Laurie B Schenkel
- Department of Medicinal Chemistry, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
AIM The study aimed to assess whether the ex vivo injection of patent blue V dye would increase lymph node yield in operative specimens of colorectal cancer. METHOD A randomized controlled trial was carried out in which patients undergoing resection for colonic cancer were allocated to patent V blue or no patent blue V dye submucosal injection of the operative specimen. The number of lymph nodes found in each group was compared. RESULTS Between 1 January and 31 December 2008, 68 patients were randomized. Thirty-three patients received patent blue V dye and 34 did not. In the former group the median number of blue nodes identified was 11, compared with a median of 9 in the no dye group. After the application of Carnoy's solution lymph node count was 16 in each group. There was no significant difference between all these results. CONCLUSION Ex vivo injection of patent blue V dye submucosally in a peritumour location did not increase the lymph node count or the percentage of specimens having more than 12 lymph nodes identified.
Collapse
Affiliation(s)
- C Wakeman
- Christchurch Hospital, Christchurch, New Zealand.
| | | | | | | | | | | | | |
Collapse
|
46
|
Yu V, Fisch T, Long AM, Tang J, Lee JH, Hierl M, Chen H, Yakowec P, Schwandner R, Emkey R. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases. ACTA ACUST UNITED AC 2011; 17:27-38. [PMID: 21859682 DOI: 10.1177/1087057111418228] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Lysine demethylase 1 (LSD1) and Jumonji C domain-containing oxygenase D2C (JMJD2C) participate in regulating the methylation status of histone H3 lysine residues. In some contexts, LSD1 and JMJD2C activity causes enhanced cellular proliferation, which may lead to tumorigenesis. The authors explored the utility of time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassays, which employed peptides consisting of the first 21 amino acids of histone H3 in which lysine 4 (H3K4) or lysine 9 (H3K9) was methylated (me) to quantify LSD1 and JMJD2C activity. The LSD1 assay monitored demethylation of the H3K4me1 peptide using an antibody that recognizes H3K4me1 but not the unmethylated peptide product. The JMJD2C assay measured demethylation of H3K9me3 with an antibody that selectively recognizes H3K9me2. The optimized conditions resulted in robust assays (Z' > 0.7) that required only 3 to 6 nM of enzyme in a reaction volume of 6 to 10 µL. These assays were used to compare the activity of different LSD1 constructs and to determine the apparent K(m) of each JMJD2C substrate. Finally, both assays were used in a high-throughput setting for identifying demethylase inhibitors. Compounds discovered by these TR-FRET methods may lead to powerful tools for ascertaining the roles of demethylases in a cellular context and ultimately for potential cancer treatments.
Collapse
|
47
|
Drew AE, Al-Assaad S, Yu V, Andrews P, Merkel P, Szilvassy S, Emkey R, Lewis R, Brake RL. Comparison of 2 cell-based phosphoprotein assays to support screening and development of an ALK inhibitor. ACTA ACUST UNITED AC 2011; 16:164-73. [PMID: 21297104 DOI: 10.1177/1087057110394657] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Anaplastic lymphoma kinase (ALK) when expressed as a fusion protein with nucleophosmin (NPM) has been implicated as a driving oncogene in a subset of lymphomas. Recent reports of ALK expression in a number of other cancers have raised the possibility that an ALK inhibitor may benefit patients with these diseases as well. In a campaign to identify and develop a selective ALK inhibitor, 2 assays were devised to measure the phosphorylation of tyrosine residue 1604 of ALK (pY(1604) ALK). Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen(®)) and phosflow platforms were used to detect modulation of pY(1604) ALK to determine the relative potency of a set of small-molecule inhibitors. Prior to making use of these assays in diverse settings, the authors attempted to ensure their equivalence with a direct comparison of their performance. The pY(1604) ALK assays correlated well both with each other and with assays of ALK enzyme activity or ALK-dependent cell proliferation. The AlphaScreen(®) assay was amenable to automation and enabled rapid, high-throughput compound assessment in an NPM-ALK-driven cell line, whereas the phosflow assay enabled the authors to characterize the activity of compounds with respect to their impact on targeted enzymes and pathways. Results show that both AlphaScreen(®) and phosflow ALK assays exhibited diverse characteristics that made them desirable for different applications but were determined to be equally sensitive and robust in the detection of inhibition of pY(1604) ALK.
Collapse
|
48
|
Liu L, Moody G, Pistillo J, Emkey R, Yu V, Doherty EM, Huang X, Kim JL, Sinclair AM. Abstract 1975: Discovery of a potent and selective Jak2 inhibitor that suppresses GM-CSF-induced STAT5 phosphorylation and Erythropoietin-induced reticulocytosis in vivo. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-1975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Essential thrombocythemia (ET), polythemia vera (PV) and myelofibrosis (MF) are myeloproliferative disorders (MPDs) characterized by a chronic excessive production of cells from one or more myeloid lineages and/or bone marrow fibrosis, and have the potential to progress to AML. Recently, gain-of-function mutations in intracellular tyrosine kinase Janus kinase 2 (Jak2) were identified to be associated with MPDs. Jak2 is a member of the Jak family of kinases including Jak1, Jak3, and Tyk2 and is the most proximal signaling component for a number of cytokine receptors. The most common Jak2 mutation identified in MPDs is a substitution of valine to phenylalanine at codon 617 (V617F) located in the pseudokinase domain, which results in the loss of its repressive function, and subsequently leads to the constitutive activation of Jak2 and downstream signaling pathways (STAT, MAP kinase, and PI3 kinase) which affect the survival, differentiation and proliferation of hematopoietic progenitors.
Highly selective Jak2 inhibitors may provide a better therapeutic window in chronic dosing settings (ET and PV patients) than non-selective Jak inhibitors. Here we report the discovery of a potent and highly selective Jak2 inhibitor, AMG-Jak2-01. In enzyme assays, AMG-Jak2-01 was potent (3 nM) and selective over other Jak family kinases (> 2000-fold over Jak1, 10-fold over Jak3 and > 400-fold over Tyk2). In isogenic BaF3 cell lines expressing constitutively active Jak kinases (Tel-Jak fusion), AMG-Jak2-01 showed over 40-fold Jak2 selectivity against Jak1 or Tyk2 and 10-fold selectivity against Jak3 based on the inhibition of STAT5 phosphorylation (pSTAT5 – detected with AlphaScreen®). In cytokine-stimulated primary PBMC or whole blood assays, AMG-Jak2-01 demonstrated more than 25-fold Jak2 selectivity over Jak1and Jak3 based on inhibition of pSTAT5 (detected by flow cytometry). In vivo, oral administration of AMG-Jak2-01 at 100 mg/kg for 1 hr inhibited GM-CSF-induced pSTAT5 by approximately 70% (p<0.01) in a mouse peripheral blood pharmacodynamic assay. Finally, two doses of AMG-Jak2-01(100 mg/kg) given 4 hrs apart were able to suppress Epo-induced reticulocytosis in the mouse by 70% (p<0.02).
In summary, we have discovered a potent Jak2 inhibitor, AMG-Jak2-01, which is selective over other Jak family members in both enzyme and cell-based assays and demonstrates inhibitory activity in GM-CSF-induced STAT5 phosphorylation and erythropoietin-induced reticulocytosis in vivo.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1975. doi:10.1158/1538-7445.AM2011-1975
Collapse
|
49
|
Yu V, Stewart R, Newhauser W. SU-GG-T-484: Dose and Dose Rate Effectiveness Factors (DDREF) for Fractionated Radiation Therapy. Med Phys 2010. [DOI: 10.1118/1.3468882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
50
|
Cervantes M, Frontini M, Yu V. 767 Cks2 overexpression leads to an increase of gammaH2AX. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71563-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|